DiscoverBest Science Medicine Podcast - BS without the BSEpisode 579: Oral Calcitonin Gene-related Peptide Antagonists: A painfully long name for the acute treatment of migraines
Episode 579: Oral Calcitonin Gene-related Peptide Antagonists: A painfully long name for the acute treatment of migraines

Episode 579: Oral Calcitonin Gene-related Peptide Antagonists: A painfully long name for the acute treatment of migraines

Update: 2024-07-22
Share

Description

In episode 579, Mike and James invite Nicholas Dugré back to the podcast to talk about the evidence around the benefits and harms of a new class of medications for the acute treatment of episodic migraines. Ubrogepant is an oral calcitonin gene-related peptide antagonist. In this case, amazing as it may sound, there are triple the number of systematic reviews than there are RCTs. Nonetheless, we go over all the evidence and at the end of the podcast you’ll know what the world knows about these agents.


Show notes


Tools for Practice


Oral Calcitonin Gene-related Peptide Antagonists: A painfully long name for the acute treatment of migraines


Comments 
In Channel
loading
00:00
00:00
x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

Episode 579: Oral Calcitonin Gene-related Peptide Antagonists: A painfully long name for the acute treatment of migraines

Episode 579: Oral Calcitonin Gene-related Peptide Antagonists: A painfully long name for the acute treatment of migraines

James McCormack